Stopping GLP-1 Drugs and Heart Risk: What the Study Shows
- 5 views
- 0 likes
- 0 comments
- All languages combined

Sign in and earn +30 points by reading this
Read to the end, wait a few seconds, then tap the claim button below.
In short
As of 13 November 2026, an observational study of 80,302 people with type 2 diabetes in Italy, published in The Lancet Regional Health – Europe on 9 November, found that those who stopped GLP-1 drugs had about twice the rate of heart attack, stroke or death [2][3]. The study cannot show that stopping caused the extra risk [5].
Key takeaways
- The study followed people with type 2 diabetes and no established cardiovascular disease who started a GLP-1 receptor agonist at 301 Italian diabetes clinics between 2004 and 2024 [2][4].
- 60.5% of the 80,302 people had stopped treatment by their last visit, defined as no GLP-1 prescription at two or more consecutive visits [2].
- In matched groups of 28,713 each, the composite of heart attack, stroke or death occurred at 3.94 per 100 person-years after stopping versus 1.96 with continued use [2].
- Death from any cause occurred at 2.23 per 100 person-years after stopping versus 0.48 with continued use, a hazard ratio of 4.81 [1][2].
- The study is observational: the reasons people stopped were not collected, and illness prompting people to stop could explain part of the link [2][3][4].
- The results apply to type 2 diabetes, not necessarily to people using GLP-1 drugs for obesity alone [2], and not to tirzepatide (Mounjaro), which was not included [5].
On this page 10 sections
- What did the study on stopping GLP-1 drugs find?
- Who was in the GLP-1 study?
- Does stopping GLP-1 drugs cause heart attacks?
- Did weight and blood pressure rise after stopping?
- Does the study apply to Ozempic or Mounjaro for weight loss?
- What happens next with this research?
- Common mistakes
- Frequently asked questions
- Glossary
- Sources
What did the study on stopping GLP-1 drugs find?
People with type 2 diabetes who stopped GLP-1 receptor agonists had about twice the rate of a heart attack, stroke or death than those who continued, in a retrospective cohort study from Italy [2][5]. It was published in The Lancet Regional Health – Europe on 9 November 2026 [2][3].
- Main result: the hazard ratio for the composite outcome was 2.03 [1].
- Event rates: 3.94 events per 100 person-years in the discontinuation group versus 1.96 in persistent users [2].
- Death from any cause: 2.23 versus 0.48 per 100 person-years, a hazard ratio of 4.81 [1][2].
- Obesity: the association was stronger in people with a BMI of 30 or above (hazard ratio 2.27) than in those below 30 (1.61) [2][5].
Euronews put the result in everyday terms: roughly four events per 100 people per year among those who stopped, compared with two per 100 among those who continued [5].
The wording around the result is cautious: the study cannot determine whether discontinuing GLP-1 drugs directly causes the increased risk [5]. That describes a link, not a proven effect.
A note on sources: the editors could not open the paper itself, so the figures in this article come from press and expert reports [2][3][4][5]. The two hazard ratios of 2.03 and 4.81 are attributed to the paper as reported in that coverage [1].
Who was in the GLP-1 study?
The study included 80,302 people with type 2 diabetes and no established cardiovascular disease who started a GLP-1 receptor agonist at one of 301 diabetes clinics in Italy between 2004 and 2024 [2][4]. Euronews says the records came from the database of the Italian Association of Clinical Diabetologists [5].
- Who stopped: 48,615 people (60.5%) had stopped by their last visit, and 31,687 (39.5%) were still on treatment [2].
- Definition of stopping: no GLP-1 prescription at two or more consecutive clinic visits [2].
- Time on treatment: Euronews reports that those who continued took a GLP-1 drug for nearly three years on average, and those who stopped for just over one year [5].
- Matching: 28,713 people from each group were matched on factors such as age, BMI, HbA1c and diabetes duration to make the groups comparable [2].
- Which drugs: only a minor share of people were on semaglutide (the drug in Ozempic), most participants received earlier-generation GLP-1 drugs, and tirzepatide (Mounjaro) was not included because it entered the Italian market after the study period [5].
The Pharmaceutical Journal notes that previous studies have found 20% to 50% of people stop GLP-1 therapy within the first year [2]. Euronews listed common reasons for stopping as gastrointestinal side effects, perceived lack of effect, high costs and concern about rare side effects [5].
Does stopping GLP-1 drugs cause heart attacks?
The study cannot show that stopping GLP-1 drugs causes heart attacks or strokes; it shows that the two are linked [5]. The authors say discontinuation may represent a higher underlying risk rather than a direct cause of increased cardiovascular risk [2].
- Reasons for stopping unknown: the study did not collect why people stopped, and socioeconomic status was not included, ABC News reported [4].
- Illness may drive stopping: illness prompting people to stop treatment may partly explain the link [2]. Clara Chow of the University of Sydney put it as discontinuation being a marker that people are sick rather than a cause of their sickness [4].
- Not only withdrawal: the authors also say the association is “unlikely to be explained solely by withdrawal of GLP-1RA therapy” [2].
Prof Naveed Sattar of the University of Glasgow, commenting for the Science Media Centre, said the results “should be interpreted as associations rather than evidence that stopping the medication directly causes higher cardiovascular or other health risks” [3]. He added that the results do not necessarily mean risks become higher than they would have been had people never started treatment [3].
Faye Riley of Diabetes UK told The Pharmaceutical Journal “we can’t tell whether stopping taking GLP-1s directly raised people’s risk of heart attack and stroke” [2].
Did weight and blood pressure rise after stopping?
Only modestly: changes in weight, blood pressure and blood sugar after stopping were small and did not differ significantly between people who later had an event and those who did not [2][5].
The researchers compared risk factors at 12 and 24 months with baseline in people who went on to have a heart attack, stroke or death and in those who did not [2]. The differences were small, and the authors say the higher risk “may not be fully explained by deterioration of traditional risk factors alone” [2].
- Possible protective effect: ABC News reported that lead author Antonio Ceriello theorised GLP-1 drugs could give direct protection to the cardiovascular system, which is lost when stopped; this is a hypothesis, not a finding [4].
- Obesity: the association was stronger in people with a BMI of 30 or above than in those below 30, but the coverage the editors read does not settle why [2][5].
Does the study apply to Ozempic or Mounjaro for weight loss?
Not necessarily: the findings may not apply to people taking GLP-1 drugs for obesity without type 2 diabetes, and tirzepatide (Mounjaro) was not included [2][5].
- Diabetes only: everyone in the study had type 2 diabetes; people using these drugs only to lose weight were not the group studied [2].
- Little semaglutide: only a minor portion of participants took semaglutide, the active ingredient in Ozempic and Wegovy [4][5].
- No tirzepatide: it entered the Italian market after the study period [5].
- No heart disease at the start: people with established cardiovascular disease were excluded [4].
Clara Chow of the University of Sydney told ABC News that the core conclusion “might be misleading” without knowing why people stopped [4]. ABC also noted that the study does not make clear whether starting and then stopping is riskier than never taking the drug [4].
Diabetes UK said that anyone with type 2 diabetes considering stopping treatment “should speak to their healthcare team first” [2].
This is not medical advice. Decisions about your own treatment belong with a qualified clinician who knows your history.
What happens next with this research?
The study authors call for further research [5], and Sattar noted that randomised evidence on what happens when people stop GLP-1 drugs is limited [3].
- Randomised trial gap: Sattar noted that randomised evidence on the cardiovascular consequences of stopping remains limited [3].
- Long-term effects: Chow told ABC News “We need more information about the long-term effects of these medications” [4].
- Reasons for stopping: until studies record why people stop, it will stay hard to separate the effect of stopping from the effect of illness [3][4].
Anyone who asks a chatbot to summarise a study like this should know why chatbots can get details wrong, which is covered in AI Hallucinations Explained: Why Chatbots Make Things Up and How to Get Accurate Answers. How AI is being tested and regulated in clinical care is explained in AI in Healthcare: What It Can Do Today, Where It Fails and How It Is Regulated.
Common mistakes
Reading the study as proof that stopping causes heart attacks
Fix: It is observational; the authors say stopping may represent a higher underlying risk rather than a direct cause [2].
Applying it to weight-loss use of Ozempic or Wegovy
Fix: Everyone had type 2 diabetes, and only a minor share took semaglutide [2][5].
Applying it to Mounjaro
Fix: Tirzepatide was not included; it entered the Italian market after the study period [5].
Blaming weight regain for the extra risk
Fix: Changes in weight, blood sugar and blood pressure after stopping were small and did not differ significantly between people with and without events [5].
Stopping or switching medicine based on a headline
Fix: Diabetes UK advises speaking to the healthcare team first [2].
Frequently asked questions
What did the study on stopping GLP-1 drugs find?
About twice the rate of heart attack, stroke or death after stopping: 3.94 vs 1.96 per 100 person-years [1].
Who was in the GLP-1 study?
80,302 people with type 2 diabetes and no established heart disease at 301 Italian clinics, 2004–2024 [2][4].
Does stopping GLP-1 drugs cause heart attacks?
Not shown: the study is observational and the reasons for stopping were not collected [3][4].
Did weight and blood pressure rise after stopping?
Only modestly, and the changes did not differ significantly between people with and without later events [5].
Glossary
- GLP-1 receptor agonist
- A medicine that mimics the gut hormone GLP-1 to lower blood sugar and appetite.
- Observational study
- Research that analyses what happened to people without assigning treatments, so it shows links rather than causes.
- Person-years
- The total time all participants were followed; 100 person-years could be 100 people for one year.
- Hazard ratio
- A measure comparing how often an event happens over time in one group versus another.
- Propensity score matching
- A method that pairs similar people from two groups to make comparisons fairer.
- Reverse causation
- When the outcome, or its early signs, causes the exposure rather than the other way round.
Sources
- GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study The Lancet Regional Health – Europe · 2026-11-09
- Stopping GLP-1s linked to twice the risk of heart attack, stroke or death in type 2 diabetes The Pharmaceutical Journal · 2026-11-12
- Expert reaction to a retrospective cohort study looking at GLP-1 RA discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes Science Media Centre · 2026-11-09
- Study links stopping Ozempic-like drugs with poor heart health outcomes ABC News (Australia) · 2026-11-10
- For diabetes patients, stopping GLP-1 drugs linked to doubled risk of heart attack, stroke, death Euronews · 2026-11-11
Comments
Top comments